CytoMed Therapeutics Limited
GDTC
Price:
$1.85
Market Cap:
$21.71M
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat...[Read more]
Industry
Biotechnology
IPO Date
2023-04-14
Stock Exchange
NASDAQ
Ticker
GDTC
PE Ratio
[-7.40]
ROE
[-54.74%]
Current Ratio
[5.81]
Dividend Yield
[0%]
Enterprise Value
[19.85M]
Dividend History
The ROE as of December 2025 (TTM) for CytoMed Therapeutics Limited (GDTC) is -54.74%
According to CytoMed Therapeutics Limited’s latest financial reports and current stock price. The company's current ROE is -54.74%. This represents a change of 292.61% compared to the average of -13.94% of the last 4 quarters.
CytoMed Therapeutics Limited (GDTC) Historical ROE (quarterly & annually)
How has GDTC ROE performed in the past?
The mean historical ROE of CytoMed Therapeutics Limited over the last ten years is -185.81%. The current -54.74% ROE has changed -70.54% with respect to the historical average. Over the past ten years (40 quarters), GDTC's ROE was at its highest in in the June 2020 quarter at 0%. The ROE was at its lowest in in the December 2022 quarter at -349.98%.
Average
-185.81%
Median
-62.09%
Minimum
-518.13%
Maximum
-28.68%
CytoMed Therapeutics Limited (GDTC) ROE by Quarter and Year
Discovering the peaks and valleys of CytoMed Therapeutics Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 817.89%
Maximum Annual ROE = -28.68%
Minimum Annual Increase = -92.91%
Minimum Annual ROE = -518.13%
| Year | ROE | Change |
|---|---|---|
| 2024 | -28.68% | -21.95% |
| 2023 | -36.75% | -92.91% |
| 2022 | -518.13% | 549.16% |
| 2021 | -79.82% | -80.40% |
| 2020 | -407.14% | 817.89% |
CytoMed Therapeutics Limited (GDTC) Average ROE
How has GDTC ROE performed in the past?
The current ROE of CytoMed Therapeutics Limited (GDTC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-194.52%
5-year avg
-214.10%
10-year avg
-185.81%
CytoMed Therapeutics Limited (GDTC) ROE vs. Peers
How is GDTC’s ROE compared to its peers?
CytoMed Therapeutics Limited’s ROE is greater than Enlivex Therapeutics Ltd. (-62.91%), greater than MetaVia Inc. (-212.00%), greater than NuCana plc (-580.99%), less than NeuroSense Therapeutics Ltd. (2.72%), greater than Lisata Therapeutics, Inc. (-78.18%), greater than CollPlant Biotechnologies Ltd. (-102.03%), greater than NeurAxis, Inc. (-340.23%), greater than Passage Bio, Inc. (-103.87%), greater than Exicure, Inc. (-110.40%), greater than Sonnet BioTherapeutics Holdings, Inc. (-4648.06%),
| Company | ROE | Market cap |
|---|---|---|
| -62.91% | $28.19M | |
| -212.00% | $16.10M | |
| -580.99% | $26.90M | |
| 2.72% | $29.60M | |
| -78.18% | $17.90M | |
| -102.03% | $26.70M | |
| -340.23% | $28.86M | |
| -103.87% | $29.19M | |
| -110.40% | $42.96M | |
| -4648.06% | $8.43M |
Build a custom stock screener for CytoMed Therapeutics Limited (GDTC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CytoMed Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
CytoMed Therapeutics Limited (GDTC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like CytoMed Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is CytoMed Therapeutics Limited's ROE?
How is the ROE calculated for CytoMed Therapeutics Limited (GDTC)?
What is the highest ROE for CytoMed Therapeutics Limited (GDTC)?
What is the 3-year average ROE for CytoMed Therapeutics Limited (GDTC)?
What is the 5-year average ROE for CytoMed Therapeutics Limited (GDTC)?
How does the current ROE for CytoMed Therapeutics Limited (GDTC) compare to its historical average?